CMPK1: A Potential Drug Target for Cancer and Regenerative Medicine

Target Name: CMPK1

NCBI ID: G51727

CMPK1

CMPK1: A Potential Drug Target for Cancer and Regenerative Medicine

CMPK1 (DCMP kinase), a gene that encodes a protein involved in cell signaling pathways, has recently been identified as a potential drug target or biomarker for various diseases. The kinase is involved in the regulation of DNA damage repair, cell adhesion, and cell survival, which are critical processes for the development and progression of many diseases, including cancer.

CMPK1 is a protein that is expressed in various tissues and cells, including the brain, pancreas, and gastrointestinal tract. It is a key regulator of the DNA damage repair pathway, which is responsible for repairing damaged DNA and preventing mutations that can lead to cancer. The kinase is involved in the regulation of several DNA repair pathways, including the Gadd gene repair pathway and the NBS pathway.

In addition to its role in DNA damage repair, CMPK1 is also involved in cell adhesion and cell survival. It is a critical regulator of cell-cell adhesion, which is essential for the development and maintenance of tissues and organs. The kinase is also involved in the regulation of cell survival, by preventing apoptosis (programmed cell death) and promoting survival signaling pathways.

The identification of CMPK1 as a potential drug target or biomarker has significant implications for the development of new treatments for various diseases. For example, CMPK1 has been shown to be highly expressed in various types of cancer, including breast, ovarian, and colorectal cancers. Therefore, targeting the kinase with drugs or other therapeutic agents that can inhibit its activity could be an effective way to treat these diseases.

In addition to its potential as a drug target, CMPK1 may also be used as a biomarker for certain diseases. The kinase is expressed in various tissues and cells, including cancer cells, which makes it an attractive target for diagnostic tests. For example, CMPK1 has been shown to be highly expressed in breast cancer cells, which could be used as a biomarker for the disease.

CMPK1 is also a promising target for regenerative medicine, as it has been shown to play a role in the regulation of stem cell proliferation and differentiation. The kinase has been shown to be involved in the regulation of stem cell self-renewal and differentiation, which are critical processes for the development of tissues and organs. Therefore, targeting the kinase with drugs or other therapeutic agents that can inhibit its activity could be an effective way to promote stem cell-based therapies for various diseases.

In conclusion, CMPK1 is a protein that is involved in several critical processes in cell signaling pathways, including DNA damage repair, cell adhesion, and cell survival. Its recent identification as a potential drug target or biomarker for various diseases has significant implications for the development of new treatments. The kinase is highly expressed in various types of cancer and has been shown to play a role in the regulation of stem cell proliferation and differentiation. Therefore, targeting the kinase with drugs or other therapeutic agents that can inhibit its activity could be an effective way to treat various diseases and promote regenerative medicine.

Protein Name: Cytidine/uridine Monophosphate Kinase 1

Functions: Catalyzes the phosphorylation of pyrimidine nucleoside monophosphates at the expense of ATP. Plays an important role in de novo pyrimidine nucleotide biosynthesis. Has preference for UMP and CMP as phosphate acceptors. Also displays broad nucleoside diphosphate kinase activity

The "CMPK1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CMPK1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets